Business Context and Reporting Period
Company: National Research Corporation (NRC Health)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2009
Business Overview: NRC Health provides survey-based performance measurement, analysis, tracking, and governance education services to the healthcare industry in the U.S. and Canada. The company operates six segments aggregated into one reporting segment, including NRC Picker, Health Care Market Guide, Payer Solutions, The Governance Institute, and My InnerView (MIV).
Key Financial Metrics
| Metric | Q1 2009 | Q1 2008 |
|---|---|---|
| Revenue | $16,739,741 | $13,453,896 |
| Operating Income | $4,373,864 | $3,301,747 |
| Net Income | $2,650,047 | $2,003,015 |
| Diluted EPS | $0.39 | $0.29 |
| Operating Cash Flow | $3,396,611 | $2,129,540 |
| Cash and Equivalents (End of Period) | $619,958 | $1,485,661 |
| Total Debt (Notes Payable) | $11,007,981 | Filing text does not provide a clear total for Q1 2008 |
| Working Capital | ($8,344,511) Deficiency | ($8,650,241) Deficiency (approx.) |
Note: Total Debt for Q1 2009 includes $2,821,022 current portion and $8,186,959 long-term portion of notes payable.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 24.4% to $16.7 million, primarily driven by the December 2008 acquisition of My InnerView (MIV), which contributed $2.3 million in revenue for the quarter.
- Expense Increases:
- Direct Expenses: Rose 22.8% to $7.3 million, largely due to MIV servicing costs and a change in accounting for Market Guide costs (expensed monthly rather than deferred).
- SG&A: Increased 11.8% to $4.0 million, driven by $800,000 in MIV-related expenses.
- Depreciation & Amortization: Surged 66.6% to $1.1 million due to MIV intangible asset amortization and accelerated depreciation of unused software.
- Profitability: Operating margin improved to 26.1% from 24.5% in the prior year period. Net income increased 32.3%.
- Liquidity: Cash and cash equivalents decreased by $488,895 during the quarter. The company maintained a working capital deficiency of $8.3 million, an improvement from the prior year's $8.6 million deficiency.
Guidance, Outlook, and Risks
Management Commentary: Management believes the company has adequate capital resources to meet projected needs. Growth is expected to be driven by increased demand for performance measurement services due to public reporting programs. The company expects to extend its revolving credit note term beyond its July 31, 2009 maturity.
Debt and Liquidity:
- Term Note: $9.0 million borrowed in Dec 2008 for MIV acquisition; 5.2% interest; balloon payment due Dec 31, 2011.
- Revolving Credit: $6.5 million facility; $2.1 million utilized as of March 31, 2009; $4.4 million borrowing capacity remaining.
Risks and Contingencies:
- Reliance on a limited number of key clients and potential non-renewal of performance tracking contracts.
- Highly competitive market with potential price pressure.
- Ability to manage growth and integrate acquisitions effectively.
- Regulatory developments in the healthcare industry.
Forward-Looking Statements: The filing includes standard disclaimers that actual results may differ materially from anticipated outcomes due to various risks.
Investor Verification Checklist
- Acquisition Integration: Verify the ongoing financial performance and integration status of the My InnerView (MIV) acquisition, which drove significant revenue and expense increases.
- Debt Covenants: Confirm continued compliance with financial ratios and covenants associated with the $9.0 million term note and revolving credit facility.
- Working Capital: Monitor the persistent working capital deficiency (approx. $8.3 million) and the company's ability to manage cash flow given the decline in cash equivalents.
- Client Concentration: Assess the risk associated with the company's reliance on a limited number of key clients and the renewal rates of performance tracking contracts.
- Amortization Impact: Review the long-term impact of increased depreciation and amortization expenses resulting from the MIV acquisition on future operating margins.